University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.
Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies.
A new biotech venture is advancing best-in-class oral and injectable therapies for obesity and cardiometabolic disorders, backed by $411 million in funding from leading global investors.
GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers.
Oxford Drug Design, the AI drug discovery company, has successfully completed additional in vivo validation in its potential first-in-class approach against multiple tumours.
Plexāā, a London-based medical device startup, is thrilled to announce a new partnership with Panasonic Manufacturing UK as their contract manufacturer for the award-winning BLOOM⁴³ medical device.
Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has achieved significant clinical and commercial milestones in its ModiFY study.
Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.
BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
